Menu
Born 1961. Board member since November 2014 and CEO since June 2017.
Anders Weilandt was CEO for Diabetes Tools Sweden AB from 2011-2016. Previously a member of the Board at Stille AB (publ) during the period 2004-2006, and also CEO from 2006-2009. Anders was CEO för Ascendia MedTech AB from 2000-2006. Anders currently has several Board assignments for various different companies. Medical electronics engineer. Anders holds an Executive MBA from Copenhagen Business School, which he acquired in 2004.
Shares: 600 000
Warrants: 2 500 000
Born 1968.
Niklas has been CFO for the Chordate Group since October 2017. Niklas works primarily as CFO and Finance Manager in a number of companies, and was previously the CEO for the consultancy company, Driven Ekonomi AB. Niklas holds an MSc in Finance from Stockholm University, which he acquired in 1992.
Shares: 106 250
Warrants: 250 000
Born 1956. Clinical Research & Medical Director since January 2012.
Jan is a dentist with over 25 years of experience within the pharmaceuticals industry. Jan was Head of Division and held other managerial posts at AstraZeneca AB between 2001 and 2010, and during the period 1998-2001 was Therapeutic Area Vice President at Pharmacia & Upjohn. During the period 1983-1998, he held a number of managerial posts at Astra AB. Jan worked as a teacher at the Dentistry College in Huddinge during the period 1981-1983. Degree from the School of Dentistry, Karolinska Institute in Stockholm, acquired in 1980.
Shares: 268 384
Warrants: 750 000
Born 1956. Head of R&D, Production and Quality since June 2012.
Jan Lindberg has had a long career within the medical technology field. He held a number of leading posts at St. Jude Medical during the period 1988-2012, including Head of Hardware Development and Group Head of Electronics Development. Prior to this he was a developer at Electrolux between 1985 and 1988 and at RIFA AB between 1981 and 1985. While studying he ran his own company from 1977 to 1981. Studied engineering at KTH in Stockholm, 1980.
Shares: 29 258
Warrants: 750 000
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).